How Selegiline ((-)-Deprenyl) Slows Brain Aging

Key Takeaways

• Selegiline selectively inhibits MAO‑B at 10 mg daily
• Food increases selegiline Cmax and AUC by threefold
• Low‑dose regimens (1.25‑5 mg) are explored for tolerability
• Higher exposure may amplify dopamine boost, affecting side‑effect risk

Pulse Analysis

Selegiline’s role as a selective MAO‑B inhibitor has made it a cornerstone in Parkinson’s disease management, where preserving dopamine stores is critical for motor control. By preventing oxidative deamination of dopamine, norepinephrine, and serotonin, the drug not only alleviates motor symptoms but also offers neuroprotective benefits that researchers are exploring in the context of brain aging. Its FDA approval for major depressive disorder further underscores its impact on mood regulation, positioning selegiline at the intersection of neurology and psychiatry.

Pharmacokinetic studies reveal that food dramatically amplifies selegiline’s absorption, boosting Cmax and AUC by at least threefold. This interaction suggests that dosing with meals can increase central dopamine availability, potentially enhancing efficacy for both Parkinson’s and depressive symptoms. However, the heightened exposure also raises concerns about hypertensive crises and serotonin syndrome, especially when combined with other serotonergic agents. Consequently, patients are turning to low‑dose regimens—often 1.25 mg to 5 mg—administered via tablet splitting, dissolution in water, or dropper techniques to fine‑tune plasma levels while minimizing adverse effects.

For clinicians, the food effect mandates a nuanced approach to prescribing: clear guidance on meal timing, dose adjustments, and vigilant monitoring for side effects become essential. The emerging off‑label use of sub‑therapeutic doses reflects a broader trend toward personalized neuropharmacology, where patients seek to harness selegiline’s anti‑aging potential without incurring classic MAO‑B inhibitor risks. Ongoing trials are evaluating whether controlled, low‑dose exposure can sustain dopamine signaling over the long term, offering a promising avenue for slowing cognitive decline. As evidence accumulates, treatment protocols are likely to evolve, integrating dietary considerations and precision dosing into standard practice.